IVI and Austria
Austrian Leadership at IVI
Chairperson Dr. Christian W. Mandl, Vaccines and Viral Vectors (2018- Present)
Influenza Vaccine Development:
In 2010, IVI initiated studies with Avir Green Hills Biotechnology AG of Austria involving sublingual administration of NS-1 deleted influenza virus constructs in animals and evaluation of the immune response and protection against experimental challenge with different virulent influenza strains.
The Delta NS1 Vaccine Platform is now a “versatile and robust technology platform for broadly protective, self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain.” https://vivaldibiosciences.com/